Ascendis Pharma

Youtube Subscribe

Open: 148.05 Close: 152.47 Change: 4.42

The best way to get information about Ascendis Pharma: Use an AI.

This document will help you to evaluate Ascendis Pharma without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ascendis Pharma are: approve, FDA, UBS, new, treatment, Group, AGs, …

Concept Map

Semantic Network

Stock Summary

Ascendis Pharma A/S focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD) The company also develops TransCon Growth Hormone for treating pediatric.

Today's Summary

UBS Group AGs holdings in Ascendis Pharma A/S were worth $4,048,000 as of its most recent filing with the SEC. UBS has a 12-month low of $64.33 and a twelve-month high of $161.00.

Today's News

UBS Group AGs holdings in Ascendis Pharma A/S were worth $4,048,000 as of its most recent filing with the SEC. UBS has a 12-month low of $64.33 and a twelve-month high of $161.00. The company last issued its quarterly earnings results on Wednesday, February 7th. UK MHRA approves new formulation of Amgens XGEVA. FDA approves Allecras EXBLIFEP for cUTI treatment. FDA approved Allecifep for cutI treatment. FDA approves a new drug for cancer patients. Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. Food & Drug Administration has set a PDUFA date of May 14, 2024.

Stock Profile

"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark."

Keywords

The game is changing. There is a new strategy to evaluate Ascendis Pharma fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ascendis Pharma are: approve, FDA, UBS, new, treatment, Group, AGs, and the most common words in the summary are: watch, introduction, episode, rightarrow, pharma, fda, ascendis, . One of the sentences in the summary was: UBS has a 12-month low of $64.33 and a twelve-month high of $161.00.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #watch #introduction #episode #rightarrow #pharma #fda #ascendis.

Read more →

Youtube Subscribe

---